Recommendations to promote equity, diversity and inclusion in decentralized clinical trials.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
23
05
2024
accepted:
26
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
Decentralized clinical trials involving the use of digital tools to facilitate remote research are gaining momentum. Rapid advancements in digital technologies have supported the adoption of these trials. These innovations facilitate virtual interactions between clinical trial teams and participants by making it easier to collect, transfer and store electronic data. While some studies have demonstrated the potential for these approaches to reduce barriers to clinical trial participation, they are associated with several challenges that may create or worsen existing health inequalities and limit the generalizability of trial results. Here we review the potential for digitally enabled and decentralized clinical trials to enhance clinical trial participation in an equitable manner. We describe the key barriers individuals from underserved groups may face, and provide recommendations to promote equity, diversity and inclusion.
Identifiants
pubmed: 39472759
doi: 10.1038/s41591-024-03323-w
pii: 10.1038/s41591-024-03323-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature America, Inc.
Références
US Food and Drug Administration. The evolving role of decentralized clinical trials and digital health technologies. FDA https://www.fda.gov/drugs/news-events-human-drugs/evolving-role-decentralized-clinical-trials-and-digital-health-technologies/ (accessed 25 September 2024).
Shen, R. et al. iinternet versus noninternet participation in a decentralized clinical trial: lessons from the ADAPTABLE study. J. Am. Heart Assoc. 12, e027899 (2023).
pubmed: 37345815
pmcid: 10356087
doi: 10.1161/JAHA.122.027899
Retzer, A. et al. A toolkit for capturing a representative and equitable sample in health research. Nat. Med. 29, 3259–3267 (2023).
pubmed: 38066209
pmcid: 10719102
doi: 10.1038/s41591-023-02665-1
Adesoye, T., Katz, M. H. G. & Offodile, A. C. 2nd Meeting trial participants where they are: decentralized clinical trials as a patient-centered paradigm for enhancing accrual and diversity in surgical and multidisciplinary trials in oncology. JCO Oncol. Pract. 19, 317–321 (2023).
pubmed: 36821820
doi: 10.1200/OP.22.00702
Nassif, M. et al. Recruitment strategies of a decentralized randomized placebo controlled clinical trial: the canagliflozin impact on health status, quality of life and functional status in heart failure (CHIEF-HF) trial. J. Card. Fail. 29, 863–869 (2023).
pubmed: 37040839
doi: 10.1016/j.cardfail.2023.04.001
Vayena, E., Blasimme, A. & Sugarman, J. Decentralised clinical trials: ethical opportunities and challenges. Lancet Digit. Health 5, e390–e394 (2023).
pubmed: 37105800
pmcid: 10129131
doi: 10.1016/S2589-7500(23)00052-3
Al, M., Levison, S., Berdel, W. E. & Andersen, D. Z. Decentralised elements in clinical trials: recommendations from the european medicines regulatory network. Lancet 401, 1339 (2023).
pubmed: 37087168
pmcid: 10119552
doi: 10.1016/S0140-6736(23)00463-4
Hanley, D. F. Jr. et al. Decentralized clinical trials in the trial innovation network: value, strategies, and lessons learned. J. Clin. Transl. Sci. 7, e170 (2023).
pubmed: 37654775
pmcid: 10465321
doi: 10.1017/cts.2023.597
Inan, O. T. et al. Digitizing clinical trials. NPJ Digit. Med. 3, 101 (2020).
pubmed: 32821856
pmcid: 7395804
doi: 10.1038/s41746-020-0302-y
National Academies of Sciences, Engineering & Medicine. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups (The National Academies Press, 2022).
Calvert, M. J. et al. Patient reported outcome assessment must be inclusive and equitable. Nat. Med. 28, 1120–1124 (2022).
Goodson, N. et al. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit. Med. 5, 58 (2022).
pubmed: 35513479
pmcid: 9072305
doi: 10.1038/s41746-022-00603-y
Aiyegbusi, O. L. et al. Digitally enabled decentralised research: opportunities to improve the efficiency of clinical trials and observational studies. BMJ Evid. Based Med. 28, 328–331 (2023).
de Las Heras, B. et al. Role of decentralized clinical trials in cancer drug development: results from a survey of oncologists and patients. Digit Health 8, 20552076221099997 (2022).
Weber, D. & Nøhr, C. Decentralized clinical trials: potentials for equity in digital health. Stud. Health Technol. Inform. 304, 91–95 (2023).
pubmed: 37347577
Dahne, J. & Hawk, L. W. Jr. Health equity and decentralized trials. JAMA 329, 2013–2014 (2023).
pubmed: 37261810
doi: 10.1001/jama.2023.6982
Krumholz, H. M. et al. The PAX LC Trial: a decentralized, phase 2, randomized, double-blind study of nirmatrelvir/ritonavir compared with placebo/ritonavir for long COVID. Am. J. Med. S0002-9343, 00271-7 (2024).
Van Norman, G. A. Decentralized clinical trials: the future of medical product development?. JACC Basic Transl. Sci. 6, 384–387 (2021).
pubmed: 33997523
pmcid: 8093545
doi: 10.1016/j.jacbts.2021.01.011
Gill, S. K. et al. Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial. Nat. Med. 30, 2030–2036 (2024).
pubmed: 39009776
pmcid: 11271403
doi: 10.1038/s41591-024-03094-4
Rosa, C., Marsch, L. A., Winstanley, E. L., Brunner, M. & Campbell, A. N. C. Using digital technologies in clinical trials: current and future applications. Contemp. Clin. Trials 100, 106219 (2021).
pubmed: 33212293
doi: 10.1016/j.cct.2020.106219
Oracle. The accelerated evolution of clinical trials in a pandemic environment. https://go.oracle.com/researchacceleratedtrials?elqCampaignId=257896/ (accessed 25 September 2024).
Cooper, L. & Jose, N. Despite negative perceptions of clinical trial conduct during the coronavirus disease 2019 (COVID-19) pandemic, are decentralized clinical trial methods here to stay? Ann. Transl. Med 11, 159 (2023).
pubmed: 36923074
pmcid: 10009564
doi: 10.21037/atm-23-5
McDermott, M. M. & Newman, A. B. Remote research and clinical trial integrity during and after the coronavirus pandemic. JAMA 325, 1935–1936 (2021).
pubmed: 33885728
doi: 10.1001/jama.2021.4609
Heads of Medicines Agencies, European Commission & European Medicines Agency. Recommendation paper on decentralised elements in clinical trials. European Commission https://health.ec.europa.eu/system/files/2023-03/mp_decentralised-elements_clinical-trials_rec_en.pdf (13 December 2022).
US Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials—guidance for industry. FDA https://www.fda.gov/media/157635/download (April 2022).
Dawson, S. et al. Trial Forge Guidance 3: randomised trials and how to recruit and retain individuals from ethnic minority groups—practical guidance to support better practice. Trials 23, 672 (2022).
pubmed: 35978338
pmcid: 9383663
doi: 10.1186/s13063-022-06553-w
Clinical Trials Transformation Initiative. CTTI recommendations: decentralized clinical trials. https://ctti-clinicaltrials.org/wp-content/uploads/2021/06/CTTI_DCT_Recs.pdf (September 2018).
The Health Research Authority & Medicines & Healthcare products Regulatory Agency. Increasing the diversity of people taking part in research. NHS Health Research Authority https://www.hra.nhs.uk/planning-and-improving-research/best-practice/increasing-diversity-people-taking-part-research/ (accessed 25 September 2024).
Betcheva, L., Kim, J. Y., Erhun, F., Oraiopoulos, N. & Getz, K. Applying systems thinking to inform decentralized clinical trial planning and deployment. Ther. Innov. Regul. Sci. 57, 1081–1098 (2023).
pubmed: 37389795
pmcid: 10400692
doi: 10.1007/s43441-023-00540-2
de Jong, A. J. et al. Opportunities and challenges for decentralized clinical trials: European regulators’ perspective. Clin. Pharmacol. Ther. 112, 344–352 (2022).
pubmed: 35488483
pmcid: 9540149
doi: 10.1002/cpt.2628
Coran, P. et al. Advancing the use of mobile technologies in clinical trials: recommendations from the clinical trials transformation initiative. Digit Biomark. 3, 145–154 (2019).
pubmed: 32095773
pmcid: 7011727
doi: 10.1159/000503957
Garcia, A. et al. Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. J. Biopharm. Stat. 32, 496–510 (2022).
pubmed: 35695137
pmcid: 9378511
doi: 10.1080/10543406.2022.2080698
Turakhia, M. P. et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Am. Heart J. 207, 66–75 (2019).
pubmed: 30392584
doi: 10.1016/j.ahj.2018.09.002
Perez, M. V. et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med. 381, 1909–1917 (2019).
pubmed: 31722151
pmcid: 8112605
doi: 10.1056/NEJMoa1901183
Petrini, C., Mannelli, C., Riva, L., Gainotti, S. & Gussoni, G. Decentralized clinical trials (DCTs): a few ethical considerations. Front. Public Health 10, 1081150 (2022).
pubmed: 36590004
pmcid: 9797802
doi: 10.3389/fpubh.2022.1081150
Garjani, A. et al. Decentralised clinical trials in multiple sclerosis research. Mult. Scler. 29, 317–325 (2023).
pubmed: 35735014
doi: 10.1177/13524585221100401
Park, J., Huh, K. Y., Chung, W. K. & Yu, K. S. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance. Transl. Clin. Pharm. 32, 41–51 (2024).
doi: 10.12793/tcp.2024.32.e2
Ghadessi, M. et al. Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. Orphanet J. Rare Dis. 18, 79 (2023).
pubmed: 37041605
pmcid: 10088572
doi: 10.1186/s13023-023-02693-7
Doherty, G. J., Goksu, M. & de Paula, B. H. R. Rethinking cancer clinical trials for COVID-19 and beyond. Nat. Cancer 1, 568–572 (2020).
pubmed: 35121973
pmcid: 7258610
doi: 10.1038/s43018-020-0083-x
Wang, X. et al. Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial. Eur. Heart J. Digit. Health 3, 426–436 (2022).
pubmed: 36712153
pmcid: 9708037
doi: 10.1093/ehjdh/ztac046
Joseph, J. et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. J. Am. Geriatr. Soc. 71, 1701–1713 (2023).
pubmed: 37082807
pmcid: 10258159
doi: 10.1111/jgs.18312
Zawada, S. J., Ruff, K. C., Sklar, T. & Demaerschalk, B. M. Towards a conceptual framework for addressing state-level barriers to decentralized clinical trials in the US. J. Clin. Transl. Sci. 7, e162 (2023).
pubmed: 37528942
pmcid: 10388410
doi: 10.1017/cts.2023.584
Bodicoat, D. H. et al. Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action. Trials 22, 880 (2021).
pubmed: 34863265
pmcid: 8643184
doi: 10.1186/s13063-021-05849-7
Dawson, S., Campbell, S. M., Giles, S. J., Morris, R. L. & Cheraghi-Sohi, S. Black and minority ethnic group involvement in health and social care research: a systematic review. Health Expect. 21, 3–22 (2018).
pubmed: 28812330
doi: 10.1111/hex.12597
van Rijssel, T. I. et al. Ethics review of decentralized clinical trials (DCTs): results of a mock ethics review. Drug Discov. Today 27, 103326 (2022).
pubmed: 35870693
doi: 10.1016/j.drudis.2022.07.011
Fu, S., Gerber, D. E. & Beg, M. S. Decentralized clinical trials in oncology: are we ready for a virtual-first paradigm? J. Clin. Oncol. 41, 181–185 (2023).
pubmed: 35994691
doi: 10.1200/JCO.22.00358
Singh, P., Burden, A. M., Natanegara, F. & Beckman, R. A. Design and execution of sustainable decentralized clinical trials. Clin. Pharmacol. Ther. 114, 802–809 (2023).
pubmed: 37489911
doi: 10.1002/cpt.3009
Makri, A. Bridging the digital divide in health care. Lancet Digit. Health 1, e204–e205 (2019).
doi: 10.1016/S2589-7500(19)30111-6
Ali, Z. et al. Exploring decentralized glucose and behaviometric monitoring of persons with type 2 diabetes in the setting of a clinical trial. J. Diabetes Sci. Technol. 17, 117–124 (2023).
pubmed: 34553637
doi: 10.1177/19322968211045656
Hall, C. L. et al. Opportunities and challenges of delivering digital clinical trials: lessons learned from a randomised controlled trial of an online behavioural intervention for children and young people. Trials 21, 1011 (2020).
pubmed: 33298127
pmcid: 7724811
doi: 10.1186/s13063-020-04902-1
Thakur, S. & Lahiry, S. Digital clinical trial: a new norm in clinical research. Perspect. Clin. Res. 12, 184–188 (2021).
pubmed: 34760644
pmcid: 8525789
doi: 10.4103/picr.PICR_278_20
Sachs, B. C. et al. The PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults (PREVENTABLE) trial: Study design and procedures for cognitive assessment and adjudication. Alzheimer’s Dement. 17, e054022 (2021).
doi: 10.1002/alz.054022
Dockendorf, M. F. et al. Digitally enabled, patient-centric clinical trials: shifting the drug development paradigm. Clin. Transl. Sci. 14, 445–459 (2021).
pubmed: 33048475
doi: 10.1111/cts.12910
Sommer, C. et al. Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp. Clin. Trials Commun. 11, 120–126 (2018).
pubmed: 30094387
pmcid: 6072894
doi: 10.1016/j.conctc.2018.06.008
Coert, R. M. H., Timmis, J. K., Boorsma, A. & Pasman, W. J. Stakeholder perspectives on barriers and facilitators for the adoption of virtual clinical trials: qualitative study. J. Med. Internet Res. 23, e26813 (2021).
pubmed: 34255673
pmcid: 8294122
doi: 10.2196/26813
Tjeertes, J. et al. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS). J. Neurodev. Disord. 15, 22 (2023).
pubmed: 37495977
pmcid: 10373389
doi: 10.1186/s11689-023-09494-w
Cafaro, T. et al. Remote and semi-automated methods to conduct a decentralized randomized clinical trial. J. Clin. Transl. Sci. 7, e153 (2023).
pubmed: 37528946
pmcid: 10388435
doi: 10.1017/cts.2023.574
Routen, A., Lekas, H. M., Harrison, J. & Khunti, K. Intersectionality in health equity research. BMJ 383, 2953 (2023).
pubmed: 38158221
doi: 10.1136/bmj.p2953
Watson, N. L., Mull, K. E., Heffner, J. L., McClure, J. B. & Bricker, J. B. Participant recruitment and retention in remote ehealth intervention trials: methods and lessons learned from a large randomized controlled trial of two web-based smoking interventions. J. Med. Internet Res. 20, e10351 (2018).
pubmed: 30143479
pmcid: 6128955
doi: 10.2196/10351
Clark, L. T. et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr. Probl. Cardiol. 44, 148–172 (2019).
pubmed: 30545650
doi: 10.1016/j.cpcardiol.2018.11.002
Ganesananthan, S., Rajkumar, C. A., Foley, M., Francis, D. & Al-Lamee, R. Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC and ORBITA-STAR. Eur. Heart J. Suppl. 24, H32–H42 (2022).
pubmed: 36382002
pmcid: 9650463
doi: 10.1093/eurheartjsupp/suac058
McKenna, K. C. et al. Investigator experiences using mobile technologies in clinical research: qualitative descriptive study. JMIR MHealth UHealth 9, e19242 (2021).
pubmed: 33576742
pmcid: 7910119
doi: 10.2196/19242
Moore, J., Goodson, N., Wicks, P. & Reites, J. What role can decentralized trial designs play to improve rare disease studies? Orphanet J. Rare Dis. 17, 240 (2022).
pubmed: 35725484
pmcid: 9207830
doi: 10.1186/s13023-022-02388-5
Sarraju, A. et al. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). NPJ Digit. Med. 5, 80 (2022).
pubmed: 35764796
pmcid: 9240050
doi: 10.1038/s41746-022-00622-9
Pennestrì, F., Banfi, G. & Tomaiuolo, R. Remote decentralized clinical trials: a new opportunity for laboratory medicine. Clin. Chem. Lab. Med. 61, 1388–1394 (2023).
pubmed: 36597971
doi: 10.1515/cclm-2022-1184
Coyle, J. et al. A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs). Trials 23, 614 (2022).
pubmed: 35907888
pmcid: 9338512
doi: 10.1186/s13063-022-06521-4
Coyle, J. et al. Learning from remote decentralised clinical trial experiences: a qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. Br. J. Clin. Pharm. 88, 1031–1042 (2022).
doi: 10.1111/bcp.15003
NIHR Applied Research Collaboration East Midlands. Equality Impact Assessment (EqIA) Toolkit. https://arc-em.nihr.ac.uk/clahrcs-store/equality-impact-assessment-eqia-toolkit (accessed 25 September 2024).
Blatch-Jones, A. et al. Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study. Trials 21, 304 (2020).
pubmed: 32245506
pmcid: 7118862
doi: 10.1186/s13063-020-04234-0
US Food and Drug Administration. Accessibility guidance and checklists. FDA https://www.fda.gov/about-fda/accessibility-fda/accessibility-guidance-and-checklists (accessed 25 September 2024).
DeCormier Plosky, W., Pluviose-Philip, M. J. & Bierer, B. E. Accessibility by Design (AbD): a toolkit for inclusion of people with disablities in clinical research. MRCT https://mrctcenter.org/diversity-in-clinical-research/tools/abd_toolkit/ (accessed 25 September 2024).
Ramsey, T. M. et al. Recruitment strategies and challenges in a large intervention trial: systolic blood pressure intervention trial. Clin. Trials 13, 319–330 (2016).
pubmed: 26911833
pmcid: 4965303
doi: 10.1177/1740774516631735
Apostolaros, M. et al. Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the clinical trials transformation initiative. Ther. Innov. Regul. Sci. 54, 779–787 (2020).
pubmed: 32557302
doi: 10.1007/s43441-019-00006-4
Dorsey, E. R., Kluger, B. & Lipset, C. H. The new normal in clinical trials: decentralized studies. Ann. Neurol. 88, 863–866 (2020).
pubmed: 32869367
doi: 10.1002/ana.25892
All of Us Research Program Investigators; Denny, J. C. et al. The ‘All of Us’ Research Program. New Engl. J. Med. 381, 668–676 (2019).
Alsdurf, B. Digital vs. decentralized trials: what’s the difference & how do I meet implementation challenges? Clinical Leader https://www.clinicalleader.com/doc/digital-vs-decentralized-trials-what-s-the-difference-how-do-i-meet-implementation-challenges-0001/ (18 November 2021).
Ridge, D. et al. Imposter participants’ in online qualitative research, a new and increasing threat to data integrity? Health Expect. 26, 941–944 (2023).
pubmed: 36797816
pmcid: 10154888
doi: 10.1111/hex.13724
Health and Care Research Wales, the National Institute for Health and Care Research (NIHR) & Chief Scientist Office. Guidance for recognising and addressing ineligible public involvement in health and care research. Health and Care Research Wales https://healthandcareresearchwales.org/sites/default/files/2024-07/Ineligible_Public_Involvement_paper_v1.pdf (accessed 25 September 2024).
Hirsch, I. B. et al. Incorporating site-less clinical trials into drug development: a framework for action. Clin. Ther. 39, 1064–1076 (2017).
pubmed: 28413148
doi: 10.1016/j.clinthera.2017.03.018
Thomas, K. A. & Kidziński, Ł. Artificial intelligence can improve patients’ experience in decentralized clinical trials. Nat. Med. 28, 2462–2463 (2022).
pubmed: 36266513
doi: 10.1038/s41591-022-02034-4
Abdelazeem, B. et al. The effectiveness of incentives for research participation: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 17, e0267534 (2022).
pubmed: 35452488
pmcid: 9032371
doi: 10.1371/journal.pone.0267534
Vellinga, A. et al. What do patients value as incentives for participation in clinical trials? A pilot discrete choice experiment. Res. Ethics 16, 1–12 (2020).
doi: 10.1177/1747016119898669
Griffith Fillipo, I. R. et al. Participant retention in a fully remote trial of digital psychotherapy: Comparison of incentive types. Front. Digit. Health 4, 963741 (2022).
pubmed: 36148211
pmcid: 9485564
doi: 10.3389/fdgth.2022.963741
Sridhara, R. et al. Cancer clinical trials beyond pandemic: report of an american statistical association biopharmaceutical section open forum discussion. Stat. Biopharm. Res. 15, 444–449 (2023).
doi: 10.1080/19466315.2022.2103181
Mowlem, F. D., Tenaerts, P., Gwaltney, C. & Oakley-Girvan, I. Regulatory acceptance of patient-reported outcome (PRO) data from bring-your-own-device (BYOD) solutions to support medical product labeling claims: let’s share the success stories to move the industry forward. Ther. Innov. Regul. Sci. 56, 531–535 (2022).
pubmed: 35534774
pmcid: 9084261
doi: 10.1007/s43441-022-00412-1
Al-Kaisey, A. M. et al. Accuracy of wrist-worn heart rate monitors for rate control assessment in atrial fibrillation. Int. J. Cardiol. 300, 161–164 (2020).
pubmed: 31787389
doi: 10.1016/j.ijcard.2019.11.120
Maass, K. F. et al. Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: promise to reality. Clin. Transl. Sci. 15, 2785–2795 (2022).
pubmed: 36129129
pmcid: 9747123
doi: 10.1111/cts.13411
Manyazewal, T. et al. Patient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial. EClinicalMedicine 56, 101820 (2023).
pubmed: 36684395
pmcid: 9853306
doi: 10.1016/j.eclinm.2022.101820
Browne, S. H. et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: a randomized controlled trial. PLoS Med. 16, e1002891 (2019).
pubmed: 31584944
pmcid: 6777756
doi: 10.1371/journal.pmed.1002891
Ramnath, S. et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Glob. Health 3, e001018 (2018).
doi: 10.1136/bmjgh-2018-001018
Wei, X. et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. Lancet 403, 913–923 (2024).
pubmed: 38309280
doi: 10.1016/S0140-6736(23)02270-5
Myers, T. L. et al. Recruitment for remote decentralized studies in parkinson’s disease. J. Parkinsons Dis. 12, 371–380 (2022).
pubmed: 34744053
pmcid: 8842745
doi: 10.3233/JPD-212935
Goodday, S. M. et al. An alternative to the light touch digital health remote study: the stress and recovery in frontline COVID-19 health care workers study. JMIR Form. Res. 5, e32165 (2021).
pubmed: 34726607
pmcid: 8668021
doi: 10.2196/32165
Leroy, V. et al. Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment? Alzheimers Res. Ther. 15, 87 (2023).
pubmed: 37106429
pmcid: 10133908
doi: 10.1186/s13195-023-01227-4
Haenel, E., Elash, C. A., Garner, K., Turner, M. & Kern, S. Flexible approaches to eCOA administration in clinical trials: the site perspective. Contemp. Clin. Trials Commun. 37, 101241 (2024).
pubmed: 38174210
doi: 10.1016/j.conctc.2023.101241
Johnson, E. & Marsh, L. Clinical research nurse utilisation and role in the conduct of decentralised clinical trials: a literature review. J. Res. Nurs. 28, 214–226 (2023).
pubmed: 37332317
pmcid: 10272696
doi: 10.1177/17449871231162497
Kotecha, D. et al. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research. Lancet Digit. Health 4, e757–e764 (2022).
pubmed: 36050271
doi: 10.1016/S2589-7500(22)00151-0
Liu, X. et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat. Med. 26, 1364–1374 (2020).
pubmed: 32908283
pmcid: 7598943
doi: 10.1038/s41591-020-1034-x
Khozin, S. & Coravos, A. Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations. Clin. Pharmacol. Ther. 106, 25–27 (2019).
pubmed: 31013350
doi: 10.1002/cpt.1441
Suman, A. et al. A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials. Trials 23, 856 (2022).
pubmed: 36203202
pmcid: 9535935
doi: 10.1186/s13063-022-06706-x
Ranganathan, P. & Pramesh, C. S. Virtual oncology research-different models and lessons learned. Curr. Opin. Support Palliat. Care 16, 117–122 (2022).
pubmed: 35929558
pmcid: 9451610
doi: 10.1097/SPC.0000000000000605
DiMasi, J. A. et al. Assessing the financial value of decentralized clinical trials. Ther. Innov. Regul. Sci. 57, 209–219 (2023).
pubmed: 36104654
doi: 10.1007/s43441-022-00454-5
Anguera, J. A., Jordan, J. T., Castaneda, D., Gazzaley, A. & Areán, P. A. Conducting a fully mobile and randomised clinical trial for depression: access, engagement and expense. BMJ Innov. 2, 14–21 (2016).
pubmed: 27019745
pmcid: 4789688
doi: 10.1136/bmjinnov-2015-000098